Mightier
PrivateLast Round
Series B
Dec 13, 2021
Total Funding Raised
$28.25M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Mightier operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series B round in December 2021.
Mightier is a digital health company that provides a bioresponsive video game platform designed to help children build emotional regulation. Developed at Boston Children's Hospital and Harvard Medical School, the program utilizes a heart rate monitor that adjusts game difficulty in real-time, enabling children to learn calming techniques. The platform, aimed at children aged 6-14, addresses challenges such as anxiety, ADHD, and anger. The company originated as a research program, became an independent entity named Neuromotion Labs in 2014, and later rebranded its product to Mightier in 2018.
Sector
Healthcare & Life Sciences
Verticals
Mental Health, Gaming, Medical Devices, Patient Engagement
Business Model
B2C
Customer Profile
Hardware + Subscription
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mightier Comparables
Compare Mightier with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Floreo | 81% | |
| Virtual Therapeutics | 79% | |
| Brain Power | 77% |
For institutional investors. Book with your work email.
Mightier Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 13, 2021 | ||||
| Grant | Feb 8, 2021 | ||||
| Series A Extension | Sep 27, 2019 | ||||
| Series A | May 1, 2019 | ||||
| Seed | Jun 19, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Mightier Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Slow Ventures | Series A, Seed |
| National Institute of Mental Health | Grant |
| DigiTx Partners | Series B |
| Sony Ventures Corporation | Series B |
| Founder Collective | Seed, Series A |
| Project 11 Ventures | Series A |
| Foxkiser | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 15, 2026
Monthly visitors increased 36% MoM.
- Apr 1, 2026
Trials at Boston Children's, Harvard, and Mass General show program efficacy matching medications.
For institutional investors. Book with your work email.
Mightier Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Mightier's valuation, stock price, and market status.
Is Mightier a public or private company?
Mightier is a private company.
What is the current stock price of Mightier?
Mightier is a private company, so its shares have no public market price. Caplight tracks Mightier's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Mightier worth (valuation)?
Valuation information for Mightier is not publicly available.
Can I buy Mightier stock?
Mightier shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Mightier's last funding round?
Mightier's most recent funding round was Series B on December 13, 2021.
Who are the main investors in Mightier?
Key investors in Mightier include Slow Ventures, DigiTx Partners, Foxkiser.
Will Mightier IPO soon?
No public IPO plans have been announced for Mightier.
How can I track Mightier secondary market activity?
Caplight tracks bids, offers, and trades in Mightier's shares on secondary markets.